Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ametinib vs ametinib + vinorelbine in EGFR-mutated advanced NSCLC (real-world, multicentre)
ChiCTR2400090618Phase 4Not yet recruiting
- Sponsor
- Anhui Chest Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Anhui Chest Hospital. Primary endpoint: Objective Response Rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400090618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090618.